Kidney Outcomes in ANCA-Glomerulonephritis According to Induction Immunosuppression and Histopathology - PubMed
a day ago
- #immunosuppression
- #ANCA-glomerulonephritis
- #kidney outcomes
- Cyclophosphamide (CYC) and rituximab (RTX) are main induction therapies for ANCA-glomerulonephritis.
- Study explores if kidney histopathology affects response to induction therapy.
- Retrospective, multicenter study with 304 patients; median baseline eGFR was 20 ml/min per 1.73 m².
- Induction therapies: CYC (59%), RTX (17%), RTX-CYC (24%).
- 50% recovered kidney function; 19.4% had kidney failure over median 42-month follow-up.
- In crescentic class, RTX monotherapy had lower eGFR recovery odds vs. CYC (OR: 0.23).
- RTX monotherapy marginally increased kidney failure risk in crescentic class vs. CYC (HR: 3.42).
- No significant outcome differences in other Berden histopathology classes.
- Conclusion: Crescentic class ANCA-glomerulonephritis patients on RTX monotherapy may have worse outcomes than CYC-based regimens.